Wait For Me: AstraZeneca’s Durvalumab Gets Its Turn At The FDA

The FDA has accepted for review AstraZeneca’s anti-PD-L1 product durvalumab in bladder cancer and granted it a priority review, setting the stage for its market debut in the second quarter of 2017. But as the fifth PD1/L1 targeting product to market it will need to attract attention to itself.

Glacial water

AstraZeneca PLC is looking forward to a possible approval in the second quarter in the US for its anti-PD-L1 product durvalumab after its BLA filing was accepted for priority review by the US FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has progressed during or after one standard platinum based regimen. Coming just weeks after Pfizer/Merck KGAA’s BLA for the PD-L1 inhibitor avelumab was accepted by the US agency, also with a priority review, it sets the product up to be the fifth PD1/PD-L1 targeting immuno-oncology product to reach the market.

If both these applications are successful, AstraZeneca and Pfizer Inc./Merck will join Roche in the PD-L1 market (it...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip